USRE31712E - Biochemical avidin-biotin multiple-layer system - Google Patents
Biochemical avidin-biotin multiple-layer system Download PDFInfo
- Publication number
- USRE31712E USRE31712E US06/532,037 US53203783A USRE31712E US RE31712 E USRE31712 E US RE31712E US 53203783 A US53203783 A US 53203783A US RE31712 E USRE31712 E US RE31712E
- Authority
- US
- United States
- Prior art keywords
- biotin
- avidin
- layer
- extender
- applying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011616 biotin Substances 0.000 title claims abstract description 39
- 229960002685 biotin Drugs 0.000 title claims abstract description 39
- 239000002365 multiple layer Substances 0.000 title abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 70
- 230000008569 process Effects 0.000 claims abstract description 69
- 108090001008 Avidin Proteins 0.000 claims abstract description 68
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 64
- 239000010410 layer Substances 0.000 claims abstract description 63
- 239000004606 Fillers/Extenders Substances 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 39
- 235000020958 biotin Nutrition 0.000 claims abstract description 35
- 229920000642 polymer Polymers 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical class C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 claims description 8
- 102000006382 Ribonucleases Human genes 0.000 claims description 5
- 108010083644 Ribonucleases Proteins 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 3
- 241000220259 Raphanus Species 0.000 claims description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 2
- 210000003743 erythrocyte Anatomy 0.000 claims description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 2
- 102000003992 Peroxidases Human genes 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000002344 surface layer Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- 108090000623 proteins and genes Proteins 0.000 abstract description 8
- 239000007787 solid Substances 0.000 abstract description 2
- 239000011324 bead Substances 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000003446 ligand Substances 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 238000007792 addition Methods 0.000 description 6
- 150000001615 biotins Chemical class 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000003252 repetitive effect Effects 0.000 description 5
- 102000004856 Lectins Human genes 0.000 description 4
- 108090001090 Lectins Proteins 0.000 description 4
- 239000002523 lectin Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 102000008857 Ferritin Human genes 0.000 description 2
- 108050000784 Ferritin Proteins 0.000 description 2
- 238000008416 Ferritin Methods 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- -1 antibody Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- VWUSNOIDPDAULP-UHFFFAOYSA-N 3-(dimethylamino)-n-(ethyliminomethylidene)-2h-pyran-2-carboxamide Chemical compound CCN=C=NC(=O)C1OC=CC=C1N(C)C VWUSNOIDPDAULP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- BAQMYDQNMFBZNA-UHFFFAOYSA-N N-biotinyl-L-lysine Natural products N1C(=O)NC2C(CCCCC(=O)NCCCCC(N)C(O)=O)SCC21 BAQMYDQNMFBZNA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- BAQMYDQNMFBZNA-MNXVOIDGSA-N biocytin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCC[C@H](N)C(O)=O)SC[C@@H]21 BAQMYDQNMFBZNA-MNXVOIDGSA-N 0.000 description 1
- 108700021042 biotin binding protein Proteins 0.000 description 1
- 102000043871 biotin binding protein Human genes 0.000 description 1
- QPFQYMONYBAUCY-ZKWXMUAHSA-N biotin sulfone Chemical compound N1C(=O)N[C@H]2CS(=O)(=O)[C@@H](CCCCC(=O)O)[C@H]21 QPFQYMONYBAUCY-ZKWXMUAHSA-N 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 1
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2991—Coated
- Y10T428/2998—Coated including synthetic resin or polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31725—Of polyamide
- Y10T428/31768—Natural source-type polyamide [e.g., casein, gelatin, etc.]
Definitions
- Avidin is a protein found in egg whites and contains four subunits. Biotin is a stable, water-soluble vitamin. Biotin and avidin interact specifically under mild and certain harsh conditions to form a strong, stable, avidin-biotin complex in which each of the four subunits of avidin bind a biotin molecule. This binding persists when biotin is attached by means of its carboxyl group to another molecule, or when avidin is attached to another molecule.
- biotin may be secured or attached to molecules on the surface of a cell or to anticellular antibodies which have been reacted onto a cell, and then subsequently is reacted with a ferritin-avidin conjugate, to provide a method for localization studies in affinity cytochemistry (see, for example, Trends in Biochemical Science, 3, N257 (1978), hereby incorporated by reference).
- Biotinyl-antibody and conjugated avidin products are offered commercially, to provide investigators with reagents for studying biochemical and immunochemical structures or processes; for example, the location or extent of cell-surface substances.
- a modified avidin-biotin system has been employed to enhance immune cellular agglutination of erythrocytes (see Clinical Chemistry, 25, No. 9, 1572 (1979), hereby incorporated by reference).
- Biotin or caproylamidobiotin was either attached directly to the cells or indirectly using biotin or caproylamidobiotin-anticellular antibody.
- the addition of avidin then achieved agglutination, and a biotin or caproylamidobiotin-conjugated macromolecule was added as an extender in conjunction with more avidin, to enhance the agglutination.
- My invention relates to a process of preparing an avidin-biotin, multiple-layer system ("layering") and to the system so prepared.
- my invention concerns a process of preparing a multiple-layer system involving repetitive, specific, monomolecular or monoparticulate layers of avidin and biotin-containing substances, to the multiple-layer system so prepared, and to the use of the system and process to change surface properties.
- My multiple-layer process and multiple-layer product comprise avidin, biotin (and any derivatives, analogs or substitutes of these which still comprise an analogous binding interaction) and a material referred to as an extender.
- An extender is defined as a molecule or substance to which one or more biotins have been attached such that these biotins still undergo binding by avidin.
- the extender useful in my invention may comprise those extenders which are described in the Clinical Chemistry publication, supra, or other biotin-modified molecules or particles. Typical and specific extenders include, but are not limited to: fibrinogen, albumin, succinylated polylysine and ribonuclease appropriately modified with biotin or biotin derivatives. These extenders may be used separately or in combination or as separate layers of different extenders as desired.
- avidin derivatives include, but are not limited to: succinyl avidin, ferritin avidin, enzyme avidin and cross-linked avidin.
- a typical example of an avidin analog is the bacterial biotin-binding protein, streptavidin, whose physical and chemical characteristics are similar to those of avidin.
- a typical example of an avidin substitute is a ligand-binding substance with multiple ligand-binding sites, such as a lectin, antibody, protein A (purified or cell-bound), etc. in conjunction with an appropriate ligand (lectins bind sugar ligands, antibodies bind hapten or antigenic determinant ligands, and protein A binds F c ligand).
- biotin derivatives include, but are not limited to: caproylamidobiotin and biocytin.
- biotin analogs are desthiobiotin and biotin sulfone and of biotin substitutes are ligands for appropriate substitute binding substances; that is, sugars, haptens or antigenic determinants, F c , for lectins, antibodies, protein A, etc., as defined above.
- the multiple-layer process is defined as the successive, repetitive attachment of avidin and extenders to a surface to build up alternate layers of each.
- the initial step could be attachment of either one of these reagents (covalently or noncovalently) to a surface, or direct firm attachment of biotins to the surface.
- layering would be achieved by repetition of the following sequence of steps (a-d) to build up successive layers of avidin and extender: (a) add avidin; (b) wash away unbound avidin; (c) add extender; and (d) wash away unbound extender, and then, optionally, perform a derivatization reaction; for example, cross-linking or modifying of functional groups, in between any of the above steps and/or after all the layers have been developed to change the properties further; for example, provide a more complete coverage of the surface, more stability, different functional groups, etc.
- Any conceivable surface may be employed, whether biological, nonbiological, organic, inorganic, or a combination of any of these, .[.any.]. .Iadd.and .Iaddend.whether formulated or existing as molecules, molecular aggregates, particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, film, etc.
- biotin or extender for example, cells, tissue, tumors, organelles, proteins, polymers, elastomers, microorganisms, viruses, nucleic acids, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic salts, chromatographic supports, test tubes, etc.; provided only that some component of the layering system can be attached firmly to initiate the process.
- the attachment of avidin to biotin or extender can proceed under mild conditions (for example, aqueous solvents and room temperature).
- My "layering" process constitutes a new process at the molecular or monoparticulate level, with an opportunity to develop specifically and to control molecular distances and constructions, with exact choices of components.
- the first layer is merely a beginning, and the overall layering process involves a careful and well-defined building up and constructing of an array of molecules or particles on a given surface in an exact and sophisticated manner, and with great variety, if so desired.
- the process and product are characterized by a unique array of characteristics which requires all of the aspects mentioned (repetitive, specific, alternate monomolecular or monoparticulate layers), and which qualitatively and/or quantitatively can differ vastly from the properties or effects achieved by the initial layer or even initial several layers.
- my process may be used to change the adsorptive, functional, catalytic, reactivity, transport, adhesive, stability, charge, toxicity, biological foreignness, frictional, electrical potential, chromatographic, pore size, rigidity, wettability, reflective, conductance, energy transfer, immunogenic, roughness, hardness, etc.
- My layering system will be demonstrated employing the process with certain caproylamidobiotin ribonuclease found particularly to be effective as an extender.
- An appropriate model surface and signal extender are used to demonstrate my layering process. Essentially, nonadsorbing conditions for all reagents were achieved in order to avoid nonspecific effects.
- An aminoethylpolyacrylamide as a surface material and a signal extender were used; that is, horse radish peroxidase modified successively with hexanediamine/carbodiimide, caproylamidobiotin NHS and succinic anhydride.
- .[.my.]. .Iadd.My .Iaddend.process includes not only the basic layering process, but also "amplification layering", to achieve relatively increasing amounts of corresponding substances in successive layers during this process.
- amplification layering is essential for many of the potential benefits and opportunities of layering to be realized fully.
- a general, basic problem with surface treatments involving coatings of one to several molecules is that complete coverages are not achieved.
- An amplification-layering process can provide complete surface coverage, because of its ability to continue to expand the surface coating in all available directions.
- FIG. 1 is a schematic illustration of the multiple-layer process and layering system of my invention.
- FIG. 2 is a schematic illustration of a specific multiple-layer process and layering system of my invention.
- FIG. 1 is a schematic illustration of a multiple-layer process and layering system of my invention, wherein the biotin is covalently bonded directly to the illustrative surface in the first step, avidin is applied in the next step, and extender (a material to which biotin groups are attached as defined previously) is added, followed by repetitive further additions of avidin and noncovalent extender with intermediate washing steps to remove excess reagents.
- biotin is covalently bonded directly to the illustrative surface in the first step
- avidin is applied in the next step
- extender a material to which biotin groups are attached as defined previously
- the layers may be mixed, that various extenders and forms of avidin (and any derivatives, analogs or substitutes of these) may be used separately, concurrently, intermittently, etc. in a given layering process, that the layering process may result in constant, increasing or decreasing amounts of corresponding substances in successive layers, and that the layers may proceed in the form of molecular and/or particulate sheets, clumps, spheres, patches, rods, tubes, etc. from the initiation sites on the surface.
- FIG. 2 shows a schematic illustration of a specific, multiple-layer process and product, wherein the surface comprises polyacrylamide particles containing reactive alkylamine groups, which then was modified by reaction with a layer of biotin-NHS esters.
- the modified surface was then coated with alternating successive layers of avidin and a biotin-ribonuclease extender material, illustrated as five successive layers, to modify the surface of the particles.
- the extent of avidin attachment in each layering step was monitored by adding an aliquot .Iadd.of .Iaddend.biotin-horse radish peroxidase (BHRPO) to each avidin layer treatment.
- BHRPO biotin-ribonuclease
- the BHPRO served as a signal extender. Appropriate washing and control steps and treatment were carried out.
- the HRPO color at 500 nanometers was measured after each avidin layering step as a measure of the amount of avidin (most specifically, available avidin-binding sites for BHRPO), and the layering process was found to generate increasing amounts of avidin with each avidin layer (amplification layering), one of the three possibilities (constant, decreasing or increasing), cited earlier.
- the color-vs.-number-of-layers is as shown in Table 1.
- Affigel-701 from Bio-Rad--an aminoethyl derivative of polyacrylamide in a bead form 1-3 microns in diameter.
- the beads were provided in an aqueous suspension at 25 ⁇ 3 ⁇ /mol of amine groups/ml.
- PBS Phosphate buffered saline
- wash buffer-- The buffer used for all washing steps was PBS containing bovine serum albumin (BSA) at 0.02% wt and Tween-20 surfactant at 0.05% wt.
- BSA bovine serum albumin
- HRPO substrate-- was freshly prepared by dissolving phenol (100 mg) and 4-aminoantipyrine (16.2 mg) in a solution composed of 0.5 M Na 2 HPO 4 (2 ml), 0.5 M KH 2 PO 4 (18 ml), water (180 ml) and 30% H 2 O 2 (20 ⁇ l).
- Silanized glass tubes--Disposable borosilicate glass tubes (12 ⁇ 75 mm) were silanized by filling with a 2% solution of chlorotrimethylsilane in benzene. The silanizing reagent was decanted after 1/2 hour, the tubes rinsed with acetone and air-dried.
- Biotin NHS ester (biotin N-hydroxysuccinimide ester)--was prepared as defined in Jasiewicz, M. M., Schoenberg, D. R., and Mueller, G. C., Exp. Cell Res. 100, 213 (1978), hereby incorporated by reference.
- BHRPO horse radish peroxidase (Worthington Biochemical)--10 mg were dissolved in 1 ml of water. This was added to a solution consisting of 1,6-hexanediamine (116 mg). 0.2 M sodium pyrophosphate (2.0 ml), water (5.0 ml) and sufficient concentrated HCl to bring the pH to 5.5. A solid water-soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopyroyl) carbodiimide (EDC) was added to the gently mixed solution at room temperature. Three separate additions of 190 mg each were made over a 1-hour period.
- BHRPO biotinyl-HRPO
- Biotin-beads suspension--Affigel-701 (5.0 ml, about 125 ⁇ mol of amine groups) was added to PBS (5.0 ml). This suspension was vortexed 10 seconds, and biotin NHS ester (43 mg, 125 ⁇ mol) dissolved in DMF (0.1 ml) was added all at once. The reaction mixture was allowed to mix end over end for 2 hours at room temperature.
- the beads were packed by centrifugation and the supernatant discarded.
- the bead pellet was resuspended in PBS and washed with 4 ⁇ 20 ml of PBS.
- the beads (biotin beads) were finally suspended in PBS (20 ml) containing NaN 3 (0.02%).
- a layer was applied to the avidin-biotin beads by suspending them in 1 ml of caproylamidobiotin RNase (BRNase approximately 60 ⁇ g/ml) for 10 minutes. The beads were then spun and the supernatants collected. The beads were then washed X3 with wash buffer. The newly added biotin residues were next reacted with avidin as above. The sequence of avidin followed by BRNase, with intermittent washing steps, was repeated four more times. This process is set forth in FIG. 2.
- the A 500 values of the diluted substrate solutions were measured on a Gilford 240 using water as a reference, and are given in Table I.
- the amount of functional enzyme on the beads is greater with each cycle of layering, and the rate of increase .[.giving.]. .Iadd.given .Iaddend.by the difference values) also is increasing significantly as the layering proceeds; for example, the value 0.255 between layers 4 and 5 is 2.96 times greater than the value 0.086 between layers 1 and 2.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Materials Engineering (AREA)
- Nanotechnology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Composite Materials (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Crystallography & Structural Chemistry (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
A multiple-layer process for applying, in alternate, successive layers, the protein, avidin, and a biotin-containing extender material to a solid surface to modify the properties of the surface and to the multiple-layer product so prepared.
Description
.Iadd.This is a continuation application of application Ser. No. 374,105, filed May 3, 1982, which is a Reissue application of U.S. Pat. No. 4,282,287, issued Aug. 4, 1981. .Iaddend.
Avidin is a protein found in egg whites and contains four subunits. Biotin is a stable, water-soluble vitamin. Biotin and avidin interact specifically under mild and certain harsh conditions to form a strong, stable, avidin-biotin complex in which each of the four subunits of avidin bind a biotin molecule. This binding persists when biotin is attached by means of its carboxyl group to another molecule, or when avidin is attached to another molecule. For example, biotin may be secured or attached to molecules on the surface of a cell or to anticellular antibodies which have been reacted onto a cell, and then subsequently is reacted with a ferritin-avidin conjugate, to provide a method for localization studies in affinity cytochemistry (see, for example, Trends in Biochemical Science, 3, N257 (1978), hereby incorporated by reference). Biotinyl-antibody and conjugated avidin products (with fluorescein, rhodamine, ferritin or horse radish peroxidase) are offered commercially, to provide investigators with reagents for studying biochemical and immunochemical structures or processes; for example, the location or extent of cell-surface substances.
A modified avidin-biotin system has been employed to enhance immune cellular agglutination of erythrocytes (see Clinical Chemistry, 25, No. 9, 1572 (1979), hereby incorporated by reference). Biotin or caproylamidobiotin was either attached directly to the cells or indirectly using biotin or caproylamidobiotin-anticellular antibody. The addition of avidin then achieved agglutination, and a biotin or caproylamidobiotin-conjugated macromolecule was added as an extender in conjunction with more avidin, to enhance the agglutination.
My invention relates to a process of preparing an avidin-biotin, multiple-layer system ("layering") and to the system so prepared. In particular, my invention concerns a process of preparing a multiple-layer system involving repetitive, specific, monomolecular or monoparticulate layers of avidin and biotin-containing substances, to the multiple-layer system so prepared, and to the use of the system and process to change surface properties.
My multiple-layer process and multiple-layer product comprise avidin, biotin (and any derivatives, analogs or substitutes of these which still comprise an analogous binding interaction) and a material referred to as an extender. An extender is defined as a molecule or substance to which one or more biotins have been attached such that these biotins still undergo binding by avidin. The extender useful in my invention may comprise those extenders which are described in the Clinical Chemistry publication, supra, or other biotin-modified molecules or particles. Typical and specific extenders include, but are not limited to: fibrinogen, albumin, succinylated polylysine and ribonuclease appropriately modified with biotin or biotin derivatives. These extenders may be used separately or in combination or as separate layers of different extenders as desired.
Typical examples of avidin derivatives include, but are not limited to: succinyl avidin, ferritin avidin, enzyme avidin and cross-linked avidin. A typical example of an avidin analog is the bacterial biotin-binding protein, streptavidin, whose physical and chemical characteristics are similar to those of avidin. A typical example of an avidin substitute is a ligand-binding substance with multiple ligand-binding sites, such as a lectin, antibody, protein A (purified or cell-bound), etc. in conjunction with an appropriate ligand (lectins bind sugar ligands, antibodies bind hapten or antigenic determinant ligands, and protein A binds Fc ligand). Typical examples of biotin derivatives include, but are not limited to: caproylamidobiotin and biocytin. Typical examples of biotin analogs are desthiobiotin and biotin sulfone and of biotin substitutes are ligands for appropriate substitute binding substances; that is, sugars, haptens or antigenic determinants, Fc, for lectins, antibodies, protein A, etc., as defined above.
The multiple-layer process is defined as the successive, repetitive attachment of avidin and extenders to a surface to build up alternate layers of each. The initial step could be attachment of either one of these reagents (covalently or noncovalently) to a surface, or direct firm attachment of biotins to the surface. For example, where the surface is, firstly, covalently bonded with biotin, then layering would be achieved by repetition of the following sequence of steps (a-d) to build up successive layers of avidin and extender: (a) add avidin; (b) wash away unbound avidin; (c) add extender; and (d) wash away unbound extender, and then, optionally, perform a derivatization reaction; for example, cross-linking or modifying of functional groups, in between any of the above steps and/or after all the layers have been developed to change the properties further; for example, provide a more complete coverage of the surface, more stability, different functional groups, etc. In my layering process, primarily or exclusively monomolecular or monoparticulate layers of avidin and extender (a single extender or various extender materials may be used in a given multiple-layer process) are built up on a surface, but the process may be relaxed by omitting washing steps, thereby possibly mixing in coverage with multimolecular or multiparticulate species.
Any conceivable surface may be employed, whether biological, nonbiological, organic, inorganic, or a combination of any of these, .[.any.]. .Iadd.and .Iaddend.whether formulated or existing as molecules, molecular aggregates, particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, film, etc. (for example, cells, tissue, tumors, organelles, proteins, polymers, elastomers, microorganisms, viruses, nucleic acids, plastics, resins, polysaccharides, silica or silica-based materials, carbon, metals, inorganic salts, chromatographic supports, test tubes, etc.); provided only that some component of the layering system can be attached firmly to initiate the process. The attachment of avidin to biotin or extender can proceed under mild conditions (for example, aqueous solvents and room temperature).
The basic concept of developing repetitive, specific, alternate, monomolecular or monoparticulate layers on a surface is .[.uprecedented.]. .Iadd.unprecedented.Iaddend.. My "layering" system bears no relation to conventional surface-treatment processes, such as painting, because of the latter's gross number of molecules and variable layer thickness involved, the poorly controlled nonspecific nature of the process, the complex and often crude nature of many of the components, and the major effect achieved by the first or second layer with subsequent layers typically leading to equivalent or diminished returns.
My "layering" process constitutes a new process at the molecular or monoparticulate level, with an opportunity to develop specifically and to control molecular distances and constructions, with exact choices of components. In my process, the first layer is merely a beginning, and the overall layering process involves a careful and well-defined building up and constructing of an array of molecules or particles on a given surface in an exact and sophisticated manner, and with great variety, if so desired. The process and product are characterized by a unique array of characteristics which requires all of the aspects mentioned (repetitive, specific, alternate monomolecular or monoparticulate layers), and which qualitatively and/or quantitatively can differ vastly from the properties or effects achieved by the initial layer or even initial several layers.
Overall my layering avidin-biotin system offers significant advantages in terms of the overall accessibility, stability, cost, size, solubility and multiple binding sites of its components, and the analogs, derivatives and substitutes for avidin and biotin are within the scope of my layering system.
A wide variety of problems associated with surfaces are now subject to a new mode of attack with my multiple-layer process and product. For example, my process may be used to change the adsorptive, functional, catalytic, reactivity, transport, adhesive, stability, charge, toxicity, biological foreignness, frictional, electrical potential, chromatographic, pore size, rigidity, wettability, reflective, conductance, energy transfer, immunogenic, roughness, hardness, etc. properties of a surface; to stabilize the inherent properties of a surface; to determine distances between sites (for example, once the distance is layered, it is shut off from further layering, or signal molecules, such as a fluorescence molecule and a fluorescence quencher, or interacting spin labels, could be used to reveal when the layers from the sites reach a certain proximity); to establish connections between sites on the same or different surfaces; to cause movement of sites on or between surfaces and, therefore, of the surfaces themselves; to disrupt a surface; to provide an exact distance between functional molecules or substances on a surface or between different surfaces; to create, study, optimize or otherwise change an interaction or binding or disruption between surfaces or between surfaces and some other substances or molecules; to provide a special microenvironment or access or protection, etc. for functional molecules or substances on surfaces; to allow larger or more complex particles to be developed by starting with a core molecule or particle and building up layers; and to allow the development of exceedingly small circuitry.
Specific examples of some uses would be to increase the extent of attachment of an enzyme, antibody, coenzyme, fluorophor, radionuclide, drug or other special atom or molecule to a surface for enhancing immunoassay, affinity chromatography, therapy, enzyme engineering, solar-energy conversion, catalysis, etc.; to reduce the pore sizes of a dialysis or filtration surface; to change retention characteristics; to change the pore size and/or surface properties of silica or silica-based particles for chromatographic or adsorption-control purposes; to exert or to enhance a physical, chemical or biological activating, inhibiting, disrupting, toxicity or killing action against a desirable or undesirable surface, such as a tumor cell, infectious microorganism, diseased tissue or disease-causing agent; to change the foreignness (for example, immunogenicity) of host tissue for reduced rejection by donor or decreased graft-vs.-host response in tissue-transplant procedures; to reduce or eliminate the foreignness of artificial tissue or implant materials (for example, reduced thrombogenic action, reduced immune or phagocytic response) in artificial-organ or-tissue operations (for example, involving plastics and other polymers, etc.); to constitute a glue or adhesive for joining tissues to other tissues or artificial surfaces; to fix tissues; to preserve foods; to use in or achieve molecular surgery; to create channels or reservoirs for reactive molecules or products; to bring together drugs, enzymes, energy-transport molecules, etc. into an arrangement and structure which optimizes their performance and action; and to create novel physiological-transport agents. Other uses of my multiple-layer process and product would be apparent to a person skilled in the art.
My layering system will be demonstrated employing the process with certain caproylamidobiotin ribonuclease found particularly to be effective as an extender.
An appropriate model surface and signal extender are used to demonstrate my layering process. Essentially, nonadsorbing conditions for all reagents were achieved in order to avoid nonspecific effects. An aminoethylpolyacrylamide as a surface material and a signal extender were used; that is, horse radish peroxidase modified successively with hexanediamine/carbodiimide, caproylamidobiotin NHS and succinic anhydride.
.[.my.]. .Iadd.My .Iaddend.process includes not only the basic layering process, but also "amplification layering", to achieve relatively increasing amounts of corresponding substances in successive layers during this process. Such amplification layering is essential for many of the potential benefits and opportunities of layering to be realized fully. For example, a general, basic problem with surface treatments involving coatings of one to several molecules is that complete coverages are not achieved. An amplification-layering process can provide complete surface coverage, because of its ability to continue to expand the surface coating in all available directions.
For the purpose of illustration only, my multiple-layer process and product will be described with reference to certain specific embodiments; however, it is recognized that those persons skilled in the art may make certain changes and modifications, all within the scope and intent of my invention.
FIG. 1 is a schematic illustration of the multiple-layer process and layering system of my invention; and
FIG. 2 is a schematic illustration of a specific multiple-layer process and layering system of my invention.
FIG. 1 is a schematic illustration of a multiple-layer process and layering system of my invention, wherein the biotin is covalently bonded directly to the illustrative surface in the first step, avidin is applied in the next step, and extender (a material to which biotin groups are attached as defined previously) is added, followed by repetitive further additions of avidin and noncovalent extender with intermediate washing steps to remove excess reagents.
It is recognized that the layers may be mixed, that various extenders and forms of avidin (and any derivatives, analogs or substitutes of these) may be used separately, concurrently, intermittently, etc. in a given layering process, that the layering process may result in constant, increasing or decreasing amounts of corresponding substances in successive layers, and that the layers may proceed in the form of molecular and/or particulate sheets, clumps, spheres, patches, rods, tubes, etc. from the initiation sites on the surface.
FIG. 2 shows a schematic illustration of a specific, multiple-layer process and product, wherein the surface comprises polyacrylamide particles containing reactive alkylamine groups, which then was modified by reaction with a layer of biotin-NHS esters. The modified surface was then coated with alternating successive layers of avidin and a biotin-ribonuclease extender material, illustrated as five successive layers, to modify the surface of the particles. The extent of avidin attachment in each layering step was monitored by adding an aliquot .Iadd.of .Iaddend.biotin-horse radish peroxidase (BHRPO) to each avidin layer treatment. The BHPRO served as a signal extender. Appropriate washing and control steps and treatment were carried out. The HRPO color at 500 nanometers was measured after each avidin layering step as a measure of the amount of avidin (most specifically, available avidin-binding sites for BHRPO), and the layering process was found to generate increasing amounts of avidin with each avidin layer (amplification layering), one of the three possibilities (constant, decreasing or increasing), cited earlier. The color-vs.-number-of-layers is as shown in Table 1.
TABLE I
______________________________________
Absorbance 500 mm (color) vs.
Number of Layering Cycles
Absorbance
No. of Layers Color Difference
Avidin (n) Absorbance
Values
______________________________________
1 .746
2 .832 .086*
3 .964 .132
4 1.124 .160
5 1.379 .255
______________________________________
*0.832 - 0.746 = 0.086
In order to illustrate more fully the nature of the invention and the manner of practicing the same, the following Example is presented:
1. Affigel-701 from Bio-Rad--an aminoethyl derivative of polyacrylamide in a bead form, 1-3 microns in diameter. The beads were provided in an aqueous suspension at 25±3 μ/mol of amine groups/ml.
2. Phosphate buffered saline (PBS)--an 0.01 M sodium phosphate, 0.15 M sodium chloride, pH 7.4.
3. Avidin--dissolved in PBS at 0.1 mg/ml based on weight.
4. Wash buffer--The buffer used for all washing steps was PBS containing bovine serum albumin (BSA) at 0.02% wt and Tween-20 surfactant at 0.05% wt.
5. HRPO substrate--was freshly prepared by dissolving phenol (100 mg) and 4-aminoantipyrine (16.2 mg) in a solution composed of 0.5 M Na2 HPO4 (2 ml), 0.5 M KH2 PO4 (18 ml), water (180 ml) and 30% H2 O2 (20 μl).
6. Silanized glass tubes--Disposable borosilicate glass tubes (12×75 mm) were silanized by filling with a 2% solution of chlorotrimethylsilane in benzene. The silanizing reagent was decanted after 1/2 hour, the tubes rinsed with acetone and air-dried.
7. Biotin NHS ester (biotin N-hydroxysuccinimide ester)--was prepared as defined in Jasiewicz, M. M., Schoenberg, D. R., and Mueller, G. C., Exp. Cell Res. 100, 213 (1978), hereby incorporated by reference.
8. Caproylamidobiotin-NHS and caproylamidobiotin-RNase (BRNase)--were prepared as defined previously (Costello, S. M. Felix, R. T. and Giese, R. W., Clin. Chem. 25, 1572 (1979), herein incorporated by reference).
9. BHRPO horse radish peroxidase (Worthington Biochemical)--10 mg were dissolved in 1 ml of water. This was added to a solution consisting of 1,6-hexanediamine (116 mg). 0.2 M sodium pyrophosphate (2.0 ml), water (5.0 ml) and sufficient concentrated HCl to bring the pH to 5.5. A solid water-soluble carbodiimide, 1-ethyl-3-(3-dimethylaminopyroyl) carbodiimide (EDC) was added to the gently mixed solution at room temperature. Three separate additions of 190 mg each were made over a 1-hour period. 11/2 hours after the first addition, the contents of the beaker were placed in a dialysis bag and dialyzed against 4×400 ml of PBS (pH=7.4). An aliquot (10 ml) from the dialysis bag was added to a solution of caproylamidobiotin-NHS ester (4.1 mg) in N,N-dimethylformamide (DMF) (0.1 ml). This solution was allowed to stand at room temperature for 11/2 hours and was then dialyzed against 4×400 ml of PBS (pH=7.4).
An aliquot (2 ml) of the above was placed in a dialysis bag and dialyzed against NaHCO3 (1 M) for 24 hours. The sample (at pH=8.6) was removed from the bag, placed in a small beaker with a magnetic mixer and reacted with .[.4.]. .Iadd.5.Iaddend.×10 μl aliquots (15 minutes apart) of succinic anhydride (40 mg) in DMF (1 ml). The sample was placed in a dialysis bag 15 minutes after the last addition and dialyzed against 4×400 ml of PBS (pH=7.4).
Assuming 100% recovery of enzyme, the concentration of biotinyl-HRPO (BHRPO) would be approximately 0.8 mg/ml. It migrated electrophoretically (cellulose acetate, pH 8.6 buffer) in a manner similar to native enzyme (although the band was more diffuse).
10. Biotin-beads suspension--Affigel-701 (5.0 ml, about 125 μmol of amine groups) was added to PBS (5.0 ml). This suspension was vortexed 10 seconds, and biotin NHS ester (43 mg, 125 μmol) dissolved in DMF (0.1 ml) was added all at once. The reaction mixture was allowed to mix end over end for 2 hours at room temperature.
The beads were packed by centrifugation and the supernatant discarded. The bead pellet was resuspended in PBS and washed with 4×20 ml of PBS. The beads (biotin beads) were finally suspended in PBS (20 ml) containing NaN3 (0.02%).
Aliquots (50 ul) of biotin-bead suspension (magnetically mixing) were placed in 12×75 mm silanized glass tubes. Each tube was treated with avidin (0.1 mg in 1 ml PBS) for 10 minutes at room temperature. The beads were then centrifuged and the supernatants collected. The beads were washed X3 with wash buffer.
A layer was applied to the avidin-biotin beads by suspending them in 1 ml of caproylamidobiotin RNase (BRNase approximately 60 μg/ml) for 10 minutes. The beads were then spun and the supernatants collected. The beads were then washed X3 with wash buffer. The newly added biotin residues were next reacted with avidin as above. The sequence of avidin followed by BRNase, with intermittent washing steps, was repeated four more times. This process is set forth in FIG. 2.
Functional biotin binding sites on avidin-biotin beads (or layered beads) were detected by suspending aliquots of the beads after each avidin step in 200 μl of BHRPO (2 μg/ml) in PBS for 30 minutes. Unbound enzyme was removed by threefold washing with wash buffer. Bound enzyme was detected by addition of HRPO substrate (4.5 ml). After 30 minutes at room temperature, the tubes were chilled in an ice bath for 5 minutes and then spun. The supernatants were decanted and diluted with PBS (4.5 ml).
The A500 values of the diluted substrate solutions were measured on a Gilford 240 using water as a reference, and are given in Table I. As seen, the amount of functional enzyme on the beads is greater with each cycle of layering, and the rate of increase .[.giving.]. .Iadd.given .Iaddend.by the difference values) also is increasing significantly as the layering proceeds; for example, the value 0.255 between layers 4 and 5 is 2.96 times greater than the value 0.086 between layers 1 and 2. This demonstrates the usefulness of layering for placing functional enzyme on a surface, increasing the amount of functional enzyme on a surface, and achieving an increasing rate of layering for the enzyme, that is, a relative increase in the amount of enzyme attached with each successive layer.
Avidin and some of the ligand binding proteins which may be employed in the practice of my invention are set forth in Table II.
TABLE II
______________________________________
Avidin and Some Other
Ligand-binding Proteins
Usual No.
Protein Ligand Affinity (Ka)
of binding sites
______________________________________
Lectins Simple sugars
10.sup.3 -10.sup.4
4
membrane sites
10.sup.6 -10.sup.7
Protein A F.sub.c of IgG
10.sup.7 4
( S. aureus)
Antibodies
Haptens 10.sup.5 -10.sup.11
2
Antigenic deter-
10.sup.5 -10.sup.11
2
minants
Avidin Biotin 10.sup.15 4
Streptavidin
Biotin -- 4
______________________________________
Claims (28)
1. A process of modifying the surface properties of a surface, which process comprises:
applying alternative, monomolecular, successive layers of first and and second materials to a surface to be modified, the first material comprising avidin and the second material comprising a .[.noncovalent,.]. biotin-modified extender, one of the materials reacted to the surface, and, thereafter, at least one additional layer of each of the first and second materials alternated, secured and .Iadd.noncovalently .Iaddend.reacted to the underlying layer, to provide a surface with the first or second material as the top surface layer thereon.
2. The process of claim 1 wherein the top surface of the process comprises the second extender material.
3. The process of claim 1 wherein the first material comprises a modified avidin adapted to react with the second extender material through the avidin portion of the modified material.
4. The process of claim 1 which includes pretreating the surface with a monomolecular layer of biotin, and wherein the first avidin material is applied over and secured to the biotin layer.
5. The process of claim 1 which includes:
(a) applying a monomolecular layer of biotin and covalently binding the biotin to the surface;
(b) applying and reacting a monomolecular layer of avidin to the biotin layer; and
(c) applying and reacting a monomolecular layer of a biotin extender material to the avidin layer.
6. The process of claim 5 which includes:
(a) applying another layer of avidin; and
(b) applying another layer of the biotin extender material to the other layer of avidin.
7. The process of claim 1, which process includes varying the concentration of the first or second material in the alternate, successive layers.
8. The process of claim 7 which includes increasing the concentration of the alternate, successive layers of the first and second materials.
9. The process of claim 7 which includes decreasing the concentration of the alternate, successive layers of the first and second materials.
10. The process of claim 1 which includes applying alternate, successive layers of approximately the same stochiometric concentration.
11. The process of claim 1 wherein the surface comprises a polymeric surface.
12. The process of claim 11 wherein the surface comprises the surface of finely-divided, polyacrylamide, polymer particles.
13. The process of claim 11 wherein the surface comprises erythrocytes.
14. The process of claim 1 wherein the surface comprises the surface of amino polyacrylamide particles, and the process comprises applying a layer of biotin-NHS esters to the surface of the particles, and, thereafter, applying successive, alternate, monomolecular layers of avidin and biotin-ribonuclease material.
15. The process of claim 1 wherein the first and second materials comprise three or more layers.
16. The process of claim 1 wherein the first and second materials comprise two monomolecular layers.
17. The process of claim 1 wherein each layer of the materials is monomolecular or monoparticulate in thickness.
18. The process of claim 1 which includes reacting at least one of the avidin layers with a biotin-horse radish peroxidase or a biotin ribonuclease as a signal extender.
19. The layering system produced by the process of claim 1.
20. The layering system produced by the process of claim 14.
21. A monomolecular-layering process of modifying the surface properties of a substrate surface of a polymer, which process comprises:
(a) applying a layer of a biotin-N-hydroxysuccinimide ester as a biotin-extender material to the surface of a polymer, to react .Iadd.covalently .Iaddend.the biotin-N-hydroxysuccinimide to the surface of the polymer;
(b) washing the polymer surface to remove unreacted biotin-N-hydroxysuccinimide;
(c) applying a layer of avidin to the washed polymer surface, to react .Iadd.noncovalently .Iaddend.the avidin with the biotin-N-hydroxysuccinimide extender material;
(d) washing the reacted surface to remove unreacted avidin;
(e) applying to the washed avidin surface a .Iadd.noncovalent .Iaddend.layer of a caproylamidobiotin NHS or RNase as a biotin-extender material;
(f) washing the reacted surface to remove unreacted biotin-extender material; and
(g) recovering the polymer having multiple layers, with the top layer composed of a biotin-extender material.
22. The process of claim 21 which includes:
(a) applying avidin to the washed polymer surface, to react another layer of avidin with the biotin-extender material;
(b) washing the reacted surface to remove unreacted avidin; and
(c) recovering a polymer having multiple layers, with the top layer composed of avidin.
23. The process of claim 22 which includes repeating the successive application of biotin-extender material and avidin, with intermittent wash steps, to provide a polymer surface with successive monomolecular layers of avidin and .[.biotinextender.]. .Iadd.biotin-extender .Iaddend.material, with the top monomolecular layer being either avidin or a biotin-extender material.
24. The process of claim 21 wherein the polymer comprises an aminoalkyl polyacrylamide polymer.
25. The process of claim 21 which includes reacting a small amount of a biotin-peroxidase or -ribonuclease material, as a signal extender for the avidin, with at least one of the applications of the avidin.
26. The polymeric-layering system produced by the process of claim 21.
27. The polymeric-layering system produced by the process of claim 22.
28. The polymeric-layering system produced by the process of claim 23.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/532,037 USRE31712E (en) | 1980-01-24 | 1983-09-14 | Biochemical avidin-biotin multiple-layer system |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/114,898 US4282287A (en) | 1980-01-24 | 1980-01-24 | Biochemical avidin-biotin multiple-layer system |
| US06/532,037 USRE31712E (en) | 1980-01-24 | 1983-09-14 | Biochemical avidin-biotin multiple-layer system |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/114,898 Reissue US4282287A (en) | 1980-01-24 | 1980-01-24 | Biochemical avidin-biotin multiple-layer system |
| US06374105 Continuation | 1982-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE31712E true USRE31712E (en) | 1984-10-23 |
Family
ID=26812650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/532,037 Expired - Lifetime USRE31712E (en) | 1980-01-24 | 1983-09-14 | Biochemical avidin-biotin multiple-layer system |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | USRE31712E (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4685900A (en) | 1983-06-01 | 1987-08-11 | Biospecific Technologies, Inc. | Therapeutic device |
| US4732811A (en) | 1982-02-28 | 1988-03-22 | Yeda Research And Development Company, Ltd. | Agarose-polyaldehyde beads and their biological application affinity chromatography, hemoperfusion, cell separation, etc. |
| US4737544A (en) | 1982-08-12 | 1988-04-12 | Biospecific Technologies, Inc. | Biospecific polymers |
| US4795459A (en) | 1987-05-18 | 1989-01-03 | Rhode Island Hospital | Implantable prosthetic device with lectin linked endothelial cells |
| US5078673A (en) * | 1988-11-14 | 1992-01-07 | Neorx Corporation | Selective removal of radiolabeled antibodies |
| US5180828A (en) * | 1990-02-09 | 1993-01-19 | Molecular Devices Corporation | Chromophoric reagents for incorporation of biotin or other haptens into macromolecules |
| US5374516A (en) * | 1987-12-18 | 1994-12-20 | Eastman Kodak Company | Avidin-and biotin immobilized reagents and methods of use |
| US5472846A (en) * | 1994-08-18 | 1995-12-05 | Rotman; M. Boris | Test kit and method for amplification and detection of antigen cells |
| US5527711A (en) * | 1993-12-13 | 1996-06-18 | Hewlett Packard Company | Method and reagents for binding chemical analytes to a substrate surface, and related analytical devices and diagnostic techniques |
| US5733254A (en) * | 1987-10-15 | 1998-03-31 | Cypress Bioscience, Inc. | Method for treating patients suffering from immune thrombocytopenic purpura |
| US5958704A (en) | 1997-03-12 | 1999-09-28 | Ddx, Inc. | Sensing system for specific substance and molecule detection |
| US6033784A (en) | 1995-04-07 | 2000-03-07 | Jacobsen; Mogens Havsteen | Method of photochemical immobilization of ligands using quinones |
| US6287285B1 (en) * | 1998-01-30 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device |
| US6531591B1 (en) | 1999-07-07 | 2003-03-11 | Exiqon A/S | Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates |
| US20040121339A1 (en) * | 2002-12-19 | 2004-06-24 | Jizhong Zhou | Special film-coated substrate for bio-microarray fabrication and use thereof |
| US20060094053A1 (en) * | 2004-11-04 | 2006-05-04 | Dimitrios Stamou | Self-assembled arrays of lipid-bilayer vesicles |
| US8895255B1 (en) | 2003-07-12 | 2014-11-25 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
| US9434937B2 (en) | 2011-03-07 | 2016-09-06 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
| US9657327B2 (en) | 2003-07-12 | 2017-05-23 | Accelerate Diagnostics, Inc. | Rapid microbial detection and antimicrobial susceptibility testing |
| US9677109B2 (en) | 2013-03-15 | 2017-06-13 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| US10023895B2 (en) | 2015-03-30 | 2018-07-17 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microogranism identification and antimicrobial agent susceptibility testing |
| US10254204B2 (en) | 2011-03-07 | 2019-04-09 | Accelerate Diagnostics, Inc. | Membrane-assisted purification |
| US10253355B2 (en) | 2015-03-30 | 2019-04-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4132528A (en) * | 1978-01-03 | 1979-01-02 | Eastman Kodak Company | Analytical element for the analysis of liquids under high pH conditions |
| US4134792A (en) * | 1976-12-06 | 1979-01-16 | Miles Laboratories, Inc. | Specific binding assay with an enzyme modulator as a labeling substance |
| US4168300A (en) * | 1975-07-09 | 1979-09-18 | Ab Kabi | Method of removal of hepatitis virus |
-
1983
- 1983-09-14 US US06/532,037 patent/USRE31712E/en not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4168300A (en) * | 1975-07-09 | 1979-09-18 | Ab Kabi | Method of removal of hepatitis virus |
| US4134792A (en) * | 1976-12-06 | 1979-01-16 | Miles Laboratories, Inc. | Specific binding assay with an enzyme modulator as a labeling substance |
| US4132528A (en) * | 1978-01-03 | 1979-01-02 | Eastman Kodak Company | Analytical element for the analysis of liquids under high pH conditions |
Non-Patent Citations (16)
| Title |
|---|
| Bayer et al., "Affinity Cytochemistry: The Localization of Lectin & Antibody Receptors on Erythrocytes Via The Avidin-Biotin Complex", FEBS Letters, pp. 240-244, vol. 68, No. 2, Oct. 1976. |
| Bayer et al., "The Avidin-Biotin Complex As a Tool in Molecular Biology" Trends in Biochemical Science 3, N257, Nov. 1978. |
| Bayer et al., Affinity Cytochemistry: The Localization of Lectin & Antibody Receptors on Erythrocytes Via The Avidin Biotin Complex , FEBS Letters, pp. 240 244, vol. 68, No. 2, Oct. 1976. * |
| Bayer et al., The Avidin Biotin Complex As a Tool in Molecular Biology Trends in Biochemical Science 3, N257, Nov. 1978. * |
| Costello et al., "Enhancement of Immune Cellular Agglutination by Use of An Avidin-Biotin System", Clinical Chem. vol. 25, No. 9, 1979. |
| Costello et al., Enhancement of Immune Cellular Agglutination by Use of An Avidin Biotin System , Clinical Chem. vol. 25, No. 9, 1979. * |
| Guesdon et al., "L'utilization de l'interaction Avidine-Biotine dans les techniques enzymatiques" (Abstract) Reunion de la Societe Francaise D'Immunoliqie, 1979. |
| Guesdon et al., "Sensitive Titration of Antibodies and Antigens Using Erythro-Immunoassay", Ann. Immunol. 131C, pp. 389-396, 1980. |
| Guesdon et al., "The Use of Avidin-Biotin Interaction in Immunoenzymatic Techniques", Journal of Histochem. & Cytochem. vol. 27, pp. 1131-1139, 1979. |
| Guesdon et al., L utilization de l interaction Avidine Biotine dans les techniques enzymatiques (Abstract) Reunion de la Societe Francaise D Immunoliqie, 1979. * |
| Guesdon et al., Sensitive Titration of Antibodies and Antigens Using Erythro Immunoassay , Ann. Immunol. 131C, pp. 389 396, 1980. * |
| Guesdon et al., The Use of Avidin Biotin Interaction in Immunoenzymatic Techniques , Journal of Histochem. & Cytochem. vol. 27, pp. 1131 1139, 1979. * |
| Heitzmann et al., "Use of the Avidin-Biotin Complex for Specific Staining of Bological Membranes . . . " Proc. Nat. Sci. vol. 71, No. 9, pp. 3537-3541, Sep. 1974. |
| Heitzmann et al., Use of the Avidin Biotin Complex for Specific Staining of Bological Membranes . . . Proc. Nat. Sci. vol. 71, No. 9, pp. 3537 3541, Sep. 1974. * |
| Jasiewicz et al., "Selective Retrieval of Biotin Labeled Cells Using _Immobilized Avidin, Experimental Cell Research 100 (1976). |
| Jasiewicz et al., Selective Retrieval of Biotin Labeled Cells Using Immobilized Avidin, Experimental Cell Research 100 (1976). * |
Cited By (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4732811A (en) | 1982-02-28 | 1988-03-22 | Yeda Research And Development Company, Ltd. | Agarose-polyaldehyde beads and their biological application affinity chromatography, hemoperfusion, cell separation, etc. |
| US4737544A (en) | 1982-08-12 | 1988-04-12 | Biospecific Technologies, Inc. | Biospecific polymers |
| US4685900A (en) | 1983-06-01 | 1987-08-11 | Biospecific Technologies, Inc. | Therapeutic device |
| US4795459A (en) | 1987-05-18 | 1989-01-03 | Rhode Island Hospital | Implantable prosthetic device with lectin linked endothelial cells |
| US5733254A (en) * | 1987-10-15 | 1998-03-31 | Cypress Bioscience, Inc. | Method for treating patients suffering from immune thrombocytopenic purpura |
| US5374516A (en) * | 1987-12-18 | 1994-12-20 | Eastman Kodak Company | Avidin-and biotin immobilized reagents and methods of use |
| US5078673A (en) * | 1988-11-14 | 1992-01-07 | Neorx Corporation | Selective removal of radiolabeled antibodies |
| US5180828A (en) * | 1990-02-09 | 1993-01-19 | Molecular Devices Corporation | Chromophoric reagents for incorporation of biotin or other haptens into macromolecules |
| US5527711A (en) * | 1993-12-13 | 1996-06-18 | Hewlett Packard Company | Method and reagents for binding chemical analytes to a substrate surface, and related analytical devices and diagnostic techniques |
| US5472846A (en) * | 1994-08-18 | 1995-12-05 | Rotman; M. Boris | Test kit and method for amplification and detection of antigen cells |
| US6033784A (en) | 1995-04-07 | 2000-03-07 | Jacobsen; Mogens Havsteen | Method of photochemical immobilization of ligands using quinones |
| US5958704A (en) | 1997-03-12 | 1999-09-28 | Ddx, Inc. | Sensing system for specific substance and molecule detection |
| US6274384B1 (en) | 1997-03-12 | 2001-08-14 | Accelr8 Technology Corporation | Method for specific substance and molecule detection |
| US6287285B1 (en) * | 1998-01-30 | 2001-09-11 | Advanced Cardiovascular Systems, Inc. | Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device |
| US6656517B2 (en) | 1998-01-30 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device |
| US6531591B1 (en) | 1999-07-07 | 2003-03-11 | Exiqon A/S | Synthesis of stable quinone and photoreactive ketone phosphoramidite reagents for solid phase synthesis of photoreactive-oligomer conjugates |
| US20040121339A1 (en) * | 2002-12-19 | 2004-06-24 | Jizhong Zhou | Special film-coated substrate for bio-microarray fabrication and use thereof |
| US20050048554A1 (en) * | 2002-12-19 | 2005-03-03 | Jizhong Zhou | Method of making and using hybrid polymeric thin films for bio-microarray applications |
| US11054420B2 (en) | 2003-07-12 | 2021-07-06 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
| US8895255B1 (en) | 2003-07-12 | 2014-11-25 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
| US9657327B2 (en) | 2003-07-12 | 2017-05-23 | Accelerate Diagnostics, Inc. | Rapid microbial detection and antimicrobial susceptibility testing |
| US9841422B2 (en) | 2003-07-12 | 2017-12-12 | Accelerate Diagnostics, Inc. | Sensitive and rapid determination of antimicrobial susceptibility |
| US20060094053A1 (en) * | 2004-11-04 | 2006-05-04 | Dimitrios Stamou | Self-assembled arrays of lipid-bilayer vesicles |
| US9434937B2 (en) | 2011-03-07 | 2016-09-06 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
| US9714420B2 (en) | 2011-03-07 | 2017-07-25 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
| US10202597B2 (en) | 2011-03-07 | 2019-02-12 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
| US10254204B2 (en) | 2011-03-07 | 2019-04-09 | Accelerate Diagnostics, Inc. | Membrane-assisted purification |
| US9677109B2 (en) | 2013-03-15 | 2017-06-13 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| US11603550B2 (en) | 2013-03-15 | 2023-03-14 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
| US10023895B2 (en) | 2015-03-30 | 2018-07-17 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microogranism identification and antimicrobial agent susceptibility testing |
| US10619180B2 (en) | 2015-03-30 | 2020-04-14 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
| US10669566B2 (en) | 2015-03-30 | 2020-06-02 | Accelerate Giagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
| US10273521B2 (en) | 2015-03-30 | 2019-04-30 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
| US10253355B2 (en) | 2015-03-30 | 2019-04-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4282287A (en) | Biochemical avidin-biotin multiple-layer system | |
| US4478914A (en) | Process for applying multiple layers of a protein and a ligand extender to a surface and to the multiple-layer system | |
| USRE31712E (en) | Biochemical avidin-biotin multiple-layer system | |
| US4656252A (en) | Amidobiotin compounds useful in a avidin-biotin multiple layering process | |
| CA1335804C (en) | Method for modifying the surface of a polymer | |
| CA1146854A (en) | Glass support coated with synthetic polymer for bioprocess | |
| US5092992A (en) | Polyethyleneimine matrixes for affinity chromatography | |
| EP0484472B1 (en) | Method for the light-induced immobilization of biomolecules on chemically "inert" surfaces | |
| CA1146855A (en) | Process of applying an adhesive water-based polymeric film to insoluble solid supports and attaching biomaterials thereto | |
| AU753093B2 (en) | Antigens embedded in thermoplastic | |
| JPS6147381B2 (en) | ||
| JPS5929817B2 (en) | Biological reagents and their production methods | |
| US5643731A (en) | Use of pairs of leucine zipper peptides in immunoassay methods | |
| US5085779A (en) | Polyethyleneimine matrixes for affinity chromatography | |
| JPH0395463A (en) | Heterojunction assay | |
| JPS60117159A (en) | Immunological analysis reagent and analysis method using the same | |
| US4572901A (en) | Method and composition for protein immobilization | |
| US4108975A (en) | Radioimmunoassay system | |
| US5436147A (en) | Heterobifunctional crosslinked agents for immobilizing molecules on plastic substrates | |
| JPH0587520B2 (en) | ||
| EP0403700B1 (en) | Polyethyleneimine matrixes for affinity chromatography | |
| JPH04501313A (en) | Immune reactant carrier with novel biocompatible intermediate coating and method for producing the same | |
| JPS6155415B2 (en) | ||
| EP0206779A1 (en) | Detecting antinuclear antibody | |
| Sänger et al. | Light-dependent immobilization of biomolecules on material and lipid bilayer membrane surfaces |